Generation of immunogenic and tolerogenic clinical-grade dendritic cells.
Publication/Presentation Date
12-1-2011
Abstract
Immunotherapy with dendritic cells (DCs), which have been manipulated ex vivo to become immunogenic or tolerogenic, has been tested in clinical trials for disease therapy. DCs are sentinels of the immune system, which after exposure to antigenic or inflammatory signals and crosstalk with effector CD4(+) T cells express high levels of costimulatory molecules and cytokines. Upregulation of either costimulatory molecules or cytokines promotes immunologic DCs, whereas their downregulation generates tolerogenic DCs (TDCs), which induce T regulatory cells (Tregs) and a state of tolerance. Immunogenic DCs are used for the therapy of infectious diseases such as HIV-1 and cancer, whereas tolerogenic DCs are used in treating various autoimmune diseases and in transplantation. DC vaccination is still at an early stage, and improvements are mainly needed in quality control of monitoring assays to generate clinical-grade DC products and to assess the effect of DC vaccination in future clinical trials. Here, we review the recent work in DC generation and monitoring approaches for DC-based trials with immunogenic or tolerogenic DCs.
Volume
51
Issue
2-3
First Page
153
Last Page
160
ISSN
1559-0755
Published In/Presented At
Kalantari, T., Kamali-Sarvestani, E., Ciric, B., Karimi, M. H., Kalantari, M., Faridar, A., Xu, H., & Rostami, A. (2011). Generation of immunogenic and tolerogenic clinical-grade dendritic cells. Immunologic research, 51(2-3), 153–160. https://doi.org/10.1007/s12026-011-8255-5
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
22105838
Department(s)
Administration and Leadership
Document Type
Article